Strategies and challenges of immunotherapy for hepatocellular carcinoma
10.3760/cma.j.cn501113-20200602-00288
- VernacularTitle:肝细胞癌免疫生物治疗的策略和挑战
- Author:
Henghui ZHANG
1
;
Hongsong CHEN
Author Information
1. 首都医科大学附属北京地坛医院传染病学研究所 100015；北京臻知医学科技有限责任公司 100083
- Keywords:
Hepatocellular carcinoma;
Immunotherapy;
Biotherapy
- From:
Chinese Journal of Hepatology
2020;28(6):457-460
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC) is a common malignant tumor in China, which seriously threatens people’s health and lives. In recent years, immunotherapy has provided new options for the treatment of HCC. Various emerging immunotherapy techniques, such as cell immunotherapy, tumor vaccines, oncolytic viruses and immune checkpoint inhibitors, are also gradually advancing to clinical applications. Immunotherapy for HCC should target the different immune characteristics of HCC patients and develop different individualized treatment strategies. In the process of formulating strategies, attention should be paid to key issues such as reversing the exhaustion of T cells, break through HCC immunosuppressive microenvironment, improving the immunotherapy specificity, enhancing the immune response of anti-HCC with adjuvant, timely and accurate evaluation of efficacy and safety, etc. In conclusion, individualization, specificity, safety and efficiency are the inevitable development trend of immunotherapy for HCC.
